FrancophonIA/ELRC3.0 huggingface dataset:
English: Caution is advised in patients with heart failure and coronary artery disease, particularly at the maximum dose of Copalia HCT, 10 mg/320 mg/25 mg, since available data in these patient populations is limited.
Estonian: Ettevaatlik peab olema südamepuudulikkuse ja koronaartõvega patsientide ravimisel, eriti kui kasutatakse Copalia HCT maksimaalset annust 10 mg/320 mg/25 mg, sest nende patsientide kohta saadud andmed on piiratud.
English: The maximum recommended dose of Copalia HCT is 10 mg/320 mg/25 mg.
Estonian: Copalia HCT maksimaalne soovitatav annus on 10 mg/320 mg/25 mg.
English: The hypokalaemic effect of hydrochlorothiazide may be increased by concomitant administration of kaliuretic diuretics, corticosteroids, laxatives, adrenocorticotropic hormone (ACTH), amphotericin, carbenoxolone, penicillin G and salicylic acid derivatives or antiarrhythmics.
Estonian: mõjutavad ravimid kortikosteroidide, lahtistite, adrenokortikotroopse hormooni (AKTH), amfoteritsiini, karbenoksolooni, penitsilliin G, salitsüülhappe derivaatide või antiarütmikumide manustamine.
English: The dose of Copalia HCT should be based on the doses of the individual components of the combination at the time of switching.
Estonian: Üleminekul peaks Copalia HCT annus põhinema kombinatsiooni üksikute komponentide annustel.
English: At week 8, the mean reductions in systolic/diastolic blood pressure were 39.7/24.7 mmHg with Copalia HCT, 32.0/19.7 mmHg with valsartan/hydrochlorothiazide, 33.5/21.5 mmHg with amlodipine/valsartan, and 31.5/19.5 mmHg with amlodipine/hydrochlorothiazide.
Estonian: 8. nädalal oli süstoolse/diastoolse vererõhu keskmine langus 39,7/24,7 mmHg Copalia HCT, 32,0/19,7 mmHg valsartaani/hüdroklorotiasiidi, 33,5/21,5 mmHg amlodipiini/valsartaani ja 31,5/19,5 mmHg amlodipiini/hüdroklorotiasiidi puhul.
English: In patients with mild to moderate hepatic impairment without cholestasis, the maximum recommended dose is 80 mg valsartan and therefore Copalia HCT is not suitable in this group of patients (see sections 4.3, 4.4 and 5.2).
Estonian: Ilma kolestaasita kerge kuni mõõduka maksakahjustuse korral on valsartaani maksimaalne soovitatav annus 80 mg ning seetõttu ei sobi Copalia HCT sellele patsientide rühmale (vt lõigud 4.3, 4.4 ja 5.2).
English: Hypromellose, substitution type 2910 (3 mPa.s) Titanium dioxide (E171) Macrogol 4000
Estonian: Hüpromelloos, asenduse tüüp 2910 (3 mPa.s) Titaandioksiid (E171)
English: When switching eligible hypertensive patients (see section 4.1) with hepatic impairment to Copalia HCT, the lowest available dose of the amlodipine component should be used.
Estonian: Viies sobivaid hüpertensiivseid maksakahjustusega patsiente (vt lõik 4.1) üle Copalia HCT-ravile, tuleb kasutada kombinatsioonravis amlodipiini minimaalset saadaolevat annust.
English: If hypokalaemia develops during hydrochlorothiazide therapy, Copalia HCT should be discontinued until stable correction of the potassium balance.
Estonian: Kui hüpokaleemia tekib ravi ajal hüdroklorotiasiidiga, tuleb Copalia HCT manustamine lõpetada kuni kaaliumitaseme stabiliseerumiseni.
English: Due to the valsartan component, Copalia HCT is contraindicated in patients with hepatic impairment (see sections 4.2 and 4.3).
Estonian: Valsartaani sisalduse tõttu on Copalia HCT vastunäidustatud maksakahjustusega patsientidel (vt lõigud 4.2 ja 4.3).
English: Copalia HCT 5 mg/160 mg/12.5 mg film-coated tablets Copalia HCT 10 mg/160 mg/12.5 mg film-coated tablets Copalia HCT 5 mg/160 mg/25 mg film-coated tablets Copalia HCT 10 mg/160 mg/25 mg film-coated tablets Copalia HCT 10 mg/320 mg/25 mg film-coated tablets
Estonian: Copalia HCT 5 mg/160 mg/12,5 mg õhukese polümeerikattega tabletid Copalia HCT 10 mg/160 mg/12,5 mg õhukese polümeerikattega tabletid Copalia HCT 5 mg/160 mg/25 mg õhukese polümeerikattega tabletid Copalia HCT 10 mg/160 mg/25 mg õhukese polümeerikattega tabletid Copalia HCT 10 mg/320 mg/25 mg õhukese polümeerikattega tabletid
English: There is no experience of overdose with Copalia HCT.
Estonian: Copalia HCT üleannustamise kogemus puudub.
English: The European Medicines Agency has waived the obligation to submit the results of studies with Copalia HCT in all subsets of the paediatric population in essential hypertension (see section 4.2 for information on paediatric use).
Estonian: Euroopa Ravimiamet ei kohusta esitama Copalia HCT'ga läbi viidud uuringute tulemusi laste kõikide alarühmade kohta, kellel esineb essentsiaalne hüpertensioon.
English: Grapefruit and grapefruit juice should not be consumed by people who are prescribed Copalia HCT.
Estonian: Inimesed, kellele on välja kirjutatud Copalia HCT'd, ei tohiks tarvitada greipfruuti ega greipfruudimahla.
English: How to take Copalia HCT
Estonian: Kuidas Copalia HCT'd võtta
English: Treatment with Copalia HCT should only start after correction of hypokalaemia and any coexisting hypomagnesaemia.
Estonian: Ravi Copalia HCT'ga tohib alustada ainult pärast hüpokaleemia ja samaaegse hüpomagneseemia korrigeerimist.
English: This is a disease in which the adrenal glands make too much of the hormone aldosterone If this applies to you, the use of Copalia HCT is not recommended.
Estonian: See on haigus, mille puhul neerupealised toodavad liiga palju aldosterooniks nimetatud hormooni.
English: Copalia HCT 5 mg/160 mg/12.5 mg film-coated tablets Copalia HCT 10 mg/160 mg/12.5 mg film-coated tablets Copalia HCT 5 mg/160 mg/25 mg film-coated tablets Copalia HCT 10 mg/160 mg/25 mg film-coated tablets Copalia HCT 10 mg/320 mg/25 mg film-coated tablets amlodipine/valsartan/hydrochlorothiazide
Estonian: Copalia HCT 5 mg/160 mg/12,5 mg õhukese polümeerikattega tabletid Copalia HCT 10 mg/160 mg/12,5 mg õhukese polümeerikattega tabletid Copalia HCT 5 mg/160 mg/25 mg õhukese polümeerikattega tabletid Copalia HCT 10 mg/160 mg/25 mg õhukese polümeerikattega tabletid Copalia HCT 10 mg/320 mg/25 mg õhukese polümeerikattega tabletid amlodipiin/valsartaan/hüdroklorotiasiid (amlodipinum/valsartanum/hydrochlorothiazidum)
English: Due to the valsartan component, Copalia HCT is contraindicated in patients with severe hepatic impairment (see section 4.3).
Estonian: Valsartaani sisalduse tõttu on Copalia HCT vastunäidustatud raske maksakahjustusega patsientidel (vt lõik 4.3).
English: Caution is advised in patients with heart failure and coronary artery disease, particularly at the maximum dose of Copalia HCT, 10 mg/320 mg/25 mg.
Estonian: Ettevaatlik peab olema südamepuudulikkuse ja koronaartõvega patsientide ravimisel, eriti kui kasutatakse Copalia HCT maksimaalset annust 10 mg/320 mg/25 mg.
English: What Copalia HCT looks like and contents of the pack Copalia HCT 5 mg/160 mg/12.5 mg film-coated tablets are white, oval tablets with “NVR” on one side and “VCL” on the other side.
Estonian: Kuidas Copalia HCT välja näeb ja pakendi sisu Copalia HCT 5 mg/160 mg/12,5 mg õhukese polümeerikattega tabletid on valged, ovaalsed tabletid, mille ühel poolel on kiri „NVR” ja teisel „VCL”.
English: Valsartan Inhibitors of the uptake transporter (rifampicin, ciclosporin) or efflux transporter (ritonavir)
Estonian: Tagasihaarde transporteri inhibiitorid (rifampitsiin, tsüklosporiin) või väljavoolu vahendava transporteri
English: No dose adjustment of Copalia HCT is required for patients with mild to moderate renal impairment (GFR ≥30 ml/min/1.73 m
Estonian: Kerge kuni mõõduka neerukahjustusega patsientidel (GFR ≥30 ml/min/1,73 m 2) ei ole vaja Copalia
English: Copalia HCT 10 mg/320 mg/25 mg film-coated tablets
Estonian: Copalia HCT 10 mg/320 mg/25 mg õhukese polümeerikattega tabletid
English: How to store Copalia HCT
Estonian: Kuidas Copalia HCT'd säilitada
English: Copalia HCT 10 mg/320 mg/25 mg film-coated tablets are brown-yellow, oval tablets with “NVR” on one side and “VFL” on the other side.
Estonian: Copalia HCT 10 mg/320 mg/25 mg õhukese polümeerikattega tabletid on pruunikaskollased, ovaalsed tabletid, mille ühel poolel on kiri „NVR” ja teisel „VFL”.
English: Copalia HCT 5 mg/160 mg/25 mg film-coated tablets are yellow, oval tablets with “NVR” on one side and “VEL” on the other side.
Estonian: Copalia HCT 5 mg/160 mg/25 mg õhukese polümeerikattega tabletid on kollased, ovaalsed tabletid, mille ühel poolel on kiri „NVR” ja teisel „VEL”.
English: Copalia HCT can be used by people aged 65 years and over at the same dose as for other adults and in the same way as they have already taken the three substances called amlodipine, valsartan and hydrochlorothiazide.
Estonian: 65-aastased ja vanemad inimesed võivad Copalia HCT'd kasutada samades annustes nagu teised täiskasvanud ning samal viisil nagu nad on siiamaani võtnud kolme toimeainet, milleks on amlodipiin, valsartaan ja hüdroklorotiasiid.. Eakatel patsientidel, iseäranis neil, kes võtavad Copalia HCT maksimaalset annust (10 mg/320 mg/25 mg), tuleks regulaarselt mõõta vererõhku.
English: EU/1/09/575/043 280 film-coated tablets
Estonian: EU/1/09/575/043 280 õhukese polümeerikattega tabletti
English: Copalia HCT 10 mg/320 mg/25 mg film-coated tablets The active substances of Copalia HCT are amlodipine (as amlodipine besylate), valsartan and hydrochlorothiazide.
Estonian: Copalia HCT 10 mg/320 mg/25 mg õhukese polümeerikattega tabletid Copalia HCT toimeained on amlodipiin (amlodipiinbesülaadina), valsartaan ja hüdroklorotiasiid.
English: EU/1/09/575/031 280 film-coated tablets
Estonian: EU/1/09/575/031 280 õhukese polümeerikattega tabletti
English: EU/1/09/575/042 98 film-coated tablets
Estonian: EU/1/09/575/042 98 õhukese polümeerikattega tabletti
English: EU/1/09/575/026 28 film-coated tablets
Estonian: EU/1/09/575/026 28 õhukese polümeerikattega tabletti
English: EU/1/09/575/004 56 film-coated tablets
Estonian: EU/1/09/575/004 56 õhukese polümeerikattega tabletti
English: Copalia HCT 10 mg/320 mg/25 mg film-coated tablets amlodipine/valsartan/hydrochlorothiaziade
Estonian: Copalia HCT 10 mg/320 mg/25 mg õhukese polümeerikattega tabletid amlodipinum/valsartanum/hydrochlorothiazidum
English: EU/1/09/575/055 280 film-coated tablets
Estonian: EU/1/09/575/055 280 õhukese polümeerikattega tabletti
English: Copalia HCT 10 mg/160 mg/12.5 mg film-coated tablets are pale yellow, oval tablets with “NVR” on one side and “VDL” on the other side.
Estonian: Copalia HCT 10 mg/160 mg/12,5 mg õhukese polümeerikattega tabletid on kahvatukollased, ovaalsed tabletid, mille ühel poolel on kiri „NVR” ja teisel „VDL”.
English: EU/1/09/575/041 90 film-coated tablets
Estonian: EU/1/09/575/041 90 õhukese polümeerikattega tabletti
English: EU/1/09/575/040 56 film-coated tablets
Estonian: EU/1/09/575/040 56 õhukese polümeerikattega tabletti
English: EU/1/09/575/006 98 film-coated tablets
Estonian: EU/1/09/575/006 98 õhukese polümeerikattega tabletti
English: EU/1/09/575/054 98 film-coated tablets
Estonian: EU/1/09/575/054 98 õhukese polümeerikattega tabletti
English: Copalia HCT 5 mg/160 mg/25 mg film-coated tablets
Estonian: Copalia HCT 5 mg/160 mg/25 mg õhukese polümeerikattega tabletid
English: Copalia HCT 5 mg/160 mg/12.5 mg film-coated tablets
Estonian: Copalia HCT 5 mg/160 mg/12,5 mg õhukese polümeerikattega tabletid
English: EU/1/09/575/007 280 film-coated tablets
Estonian: EU/1/09/575/007 280 õhukese polümeerikattega tabletti
English: EU/1/09/575/005 90 film-coated tablets
Estonian: EU/1/09/575/005 90 õhukese polümeerikattega tabletti
English: EU/1/09/575/016 56 film-coated tablets
Estonian: EU/1/09/575/016 56 õhukese polümeerikattega tabletti
English: Copalia HCT 10 mg/160 mg/25 mg film-coated tablets
Estonian: Copalia HCT 10 mg/160 mg/25 mg õhukese polümeerikattega tabletid
English: EU/1/09/575/049 14 film-coated tablets
Estonian: EU/1/09/575/049 14 õhukese polümeerikattega tabletti
English: EU/1/09/575/001 14 film-coated tablets
Estonian: EU/1/09/575/001 14 õhukese polümeerikattega tabletti
English: EU/1/09/575/030 98 film-coated tablets
Estonian: EU/1/09/575/030 98 õhukese polümeerikattega tabletti
English: EU/1/09/575/019 280 film-coated tablets
Estonian: EU/1/09/575/019 280 õhukese polümeerikattega tabletti
English: EU/1/09/575/038 28 film-coated tablets
Estonian: EU/1/09/575/038 28 õhukese polümeerikattega tabletti
English: EU/1/09/575/018 98 film-coated tablets
Estonian: EU/1/09/575/018 98 õhukese polümeerikattega tabletti
English: EU/1/09/575/053 90 film-coated tablets
Estonian: EU/1/09/575/053 90 õhukese polümeerikattega tabletti
English: EU/1/09/575/029 90 film-coated tablets
Estonian: EU/1/09/575/029 90 õhukese polümeerikattega tabletti
English: Copalia HCT 10 mg/160 mg/12.5 mg film-coated tablets
Estonian: Copalia HCT 10 mg/160 mg/12,5 mg õhukese polümeerikattega tabletid
English: EU/1/09/575/027 30 film-coated tablets
Estonian: EU/1/09/575/027 30 õhukese polümeerikattega tabletti
English: EU/1/09/575/052 56 film-coated tablets
Estonian: EU/1/09/575/052 56 õhukese polümeerikattega tabletti
English: EU/1/09/575/037 14 film-coated tablets
Estonian: EU/1/09/575/037 14 õhukese polümeerikattega tabletti
English: EU/1/09/575/014 28 film-coated tablets
Estonian: EU/1/09/575/014 28 õhukese polümeerikattega tabletti
English: Copalia HCT 10 mg/160 mg/25 mg film-coated tablets are brown-yellow, oval tablets with “NVR” on one side and “VHL” on the other side.
Estonian: Copalia HCT 10 mg/160 mg/25 mg õhukese polümeerikattega tabletid on pruunikaskollased, ovaalsed tabletid, mille ühel poolel on kiri „NVR” ja teisel „VHL”.
English: EU/1/09/575/015 30 film-coated tablets
Estonian: EU/1/09/575/015 30 õhukese polümeerikattega tabletti
English: Copalia HCT 5 mg/160 mg/25 mg film-coated tablets The active substances of Copalia HCT are amlodipine (as amlodipine besylate), valsartan and hydrochlorothiazide.
Estonian: Copalia HCT 5 mg/160 mg/25 mg õhukese polümeerikattega tabletid Copalia HCT toimeained on amlodipiin (amlodipiinbesülaadina), valsartaan ja hüdroklorotiasiid.
English: EU/1/09/575/025 14 film-coated tablets
Estonian: EU/1/09/575/025 14 õhukese polümeerikattega tabletti
English: EU/1/09/575/039 30 film-coated tablets
Estonian: EU/1/09/575/039 30 õhukese polümeerikattega tabletti
English: Copalia HCT 5 mg/160 mg/12.5 mg film-coated tablets The active substances of Copalia HCT are amlodipine (as amlodipine besylate), valsartan and hydrochlorothiazide.
Estonian: Copalia HCT 5 mg/160 mg/12,5 mg õhukese polümeerikattega tabletid Copalia HCT toimeained on amlodipiin (amlodipiinbesülaadina), valsartaan ja hüdroklorotiasiid.
English: EU/1/09/575/017 90 film-coated tablets
Estonian: EU/1/09/575/017 90 õhukese polümeerikattega tabletti
English: EU/1/09/575/002 28 film-coated tablets
Estonian: EU/1/09/575/002 28 õhukese polümeerikattega tabletti
English: EU/1/09/575/032 56 x 1 film-coated tablet (unit dose) EU/1/09/575/033 98 x 1 film-coated tablet (unit dose) EU/1/09/575/034 280 x 1 film-coated tablet (unit dose)
Estonian: EU/1/09/575/032 56 x 1 õhukese polümeerikattega tablett (üksikannus) EU/1/09/575/033 98 x 1 õhukese polümeerikattega tablett (üksikannus) EU/1/09/575/034 280 x 1 õhukese polümeerikattega tablett (üksikannus)
English: EU/1/09/575/003 30 film-coated tablets
Estonian: EU/1/09/575/003 30 õhukese polümeerikattega tabletti
English: EU/1/09/575/051 30 film-coated tablets
Estonian: EU/1/09/575/051 30 õhukese polümeerikattega tabletti
English: Copalia HCT 10 mg/160 mg/25 mg film-coated tablets The active substances of Copalia HCT are amlodipine (as amlodipine besylate), valsartan and hydrochlorothiazide.
Estonian: Copalia HCT 10 mg/160 mg/25 mg õhukese polümeerikattega tabletid Copalia HCT toimeained on amlodipiin (amlodipiinbesülaadina), valsartaan ja hüdroklorotiasiid.
English: Copalia HCT 10 mg/160 mg/12.5 mg film-coated tablets The active substances of Copalia HCT are amlodipine (as amlodipine besylate), valsartan and hydrochlorothiazide.
Estonian: Copalia HCT 10 mg/160 mg/12,5 mg õhukese polümeerikattega tabletid Copalia HCT toimeained on amlodipiin (amlodipiinbesülaadina), valsartaan ja hüdroklorotiasiid.
English: EU/1/09/575/044 56 x 1 film-coated tablet (unit dose) EU/1/09/575/045 98 x 1 film-coated tablet (unit dose) EU/1/09/575/046 280 x 1 film-coated tablet (unit dose)
Estonian: EU/1/09/575/044 56 x 1 õhukese polümeerikattega tablett (üksikannus) EU/1/09/575/045 98 x 1 õhukese polümeerikattega tablett (üksikannus) EU/1/09/575/046 280 x 1 õhukese polümeerikattega tablett (üksikannus)
English: Copalia HCT 5 mg/160 mg/25 mg film-coated tablets amlodipine/valsartan/hydrochlorothiaziade
Estonian: Copalia HCT 5 mg/160 mg/25 mg õhukese polümeerikattega tabletid amlodipinum/valsartanum/hydrochlorothiazidum
English: EU/1/09/575/008 56 x 1 film-coated tablet (unit dose) EU/1/09/575/009 98 x 1 film-coated tablet (unit dose) EU/1/09/575/010 280 x 1 film-coated tablet (unit dose)
Estonian: EU/1/09/575/008 56 x 1 õhukese polümeerikattega tablett (üksikannus) EU/1/09/575/009 98 x 1 õhukese polümeerikattega tablett (üksikannus) EU/1/09/575/010 280 x 1 õhukese polümeerikattega tablett (üksikannus)
English: EU/1/09/575/050 28 film-coated tablets
Estonian: EU/1/09/575/050 28 õhukese polümeerikattega tabletti
English: EU/1/09/575/056 56 x 1 film-coated tablet (unit dose) EU/1/09/575/057 98 x 1 film-coated tablet (unit dose) EU/1/09/575/058 280 x 1 film-coated tablet (unit dose)
Estonian: EU/1/09/575/056 56 x 1 õhukese polümeerikattega tablett (üksikannus) EU/1/09/575/057 98 x 1 õhukese polümeerikattega tablett (üksikannus) EU/1/09/575/058 280 x 1 õhukese polümeerikattega tablett (üksikannus)
English: Copalia HCT 10 mg/160 mg/25 mg film-coated tablets amlodipine/valsartan/hydrochlorothiaziade
Estonian: Copalia HCT 10 mg/160 mg/25 mg õhukese polümeerikattega tabletid amlodipinum/valsartanum/hydrochlorothiazidum
English: Copalia HCT 5 mg/160 mg/12.5 mg film-coated tablets amlodipine/valsartan/hydrochlorothiaziade
Estonian: Copalia HCT 5 mg/160 mg/12,5 mg õhukese polümeerikattega tabletid amlodipinum/valsartanum/hydrochlorothiazidum
English: Copalia HCT 10 mg/160 mg/12.5 mg film-coated tablets amlodipine/valsartan/hydrochlorothiaziade
Estonian: Copalia HCT 10 mg/160 mg/12,5 mg õhukese polümeerikattega tabletid amlodipinum/valsartanum/hydrochlorothiazidum
English: Each film-coated tablet contains 10 mg amlodipine (as amlodipine besylate), 320 mg valsartan, and 25 mg hydrochlorothiazide.
Estonian: Iga õhukese polümeerikattega tablett sisaldab 10 mg amlodipiini (amlodipinum) (amlodipiinbesülaadina), 320 mg valsartaani (valsartanum) ja 25 mg hüdroklorotiasiidi (hydrochlorothiazidum).
English: EU/1/09/575/020 56 x 1 film-coated tablet (unit dose) EU/1/09/575/021 98 x 1 film-coated tablet (unit dose) EU/1/09/575/022 280 x 1 film-coated tablet (unit dose)
Estonian: EU/1/09/575/020 56 x 1 õhukese polümeerikattega tablett (üksikannus) EU/1/09/575/021 98 x 1 õhukese polümeerikattega tablett (üksikannus) EU/1/09/575/022 280 x 1 õhukese polümeerikattega tablett (üksikannus)
English: EU/1/09/575/013 14 film-coated tablets
Estonian: EU/1/09/575/013 14 õhukese polümeerikattega tabletti
English: EU/1/09/575/036 280 film-coated tablets (multipack, 20 cartons of 14 tablets) EU/1/09/575/035 280 film-coated tablets (multipack, 4 cartons of 70 tablets) (unit dose)
Estonian: EU/1/09/569/036 280 õhukese polümeerikattega tabletti (hulgipakend, 20 karpi, igaühes 14 tabletti) EU/1/09/569/035 280 õhukese polümeerikattega tabletti (hulgipakend, 4 karpi, igaühes 70 tabletti) (üheannuseline)
English: EU/1/09/575/048 280 film-coated tablets (multipack, 20 cartons of 14 tablets) EU/1/09/575/047 280 film-coated tablets (multipack, 4 cartons of 70 tablets) (unit dose)
Estonian: EU/1/09/569/048 280 õhukese polümeerikattega tabletti (hulgipakend, 20 karpi, igaühes 14 tabletti) EU/1/09/569/047 280 õhukese polümeerikattega tabletti (hulgipakend, 4 karpi, igaühes 70 tabletti) (üheannuseline)
English: EU/1/09/575/028 56 film-coated tablets
Estonian: EU/1/09/575/028 56 õhukese polümeerikattega tabletti
English: EU/1/09/575/060 280 film-coated tablets (multipack, 20 cartons of 14 tablets) EU/1/09/575/059 280 film-coated tablets (multipack, 4 cartons of 70 tablets) (unit dose)
Estonian: EU/1/09/569/060 280 õhukese polümeerikattega tabletti (hulgipakend, 20 karpi, igaühes 14 tabletti) EU/1/09/569/059 280 õhukese polümeerikattega tabletti (hulgipakend, 4 karpi, igaühes 70 tabletti) (üheannuseline)
English: Each film-coated tablet contains 10 mg amlodipine (as amlodipine besylate),160 mg valsartan, and 12.5 mg hydrochlorothiazide.
Estonian: Iga õhukese polümeerikattega tablett sisaldab 10 mg amlodipiini (amlodipinum) (amlodipiinbesülaadina), 160 mg valsartaani (valsartanum) ja 12,5 mg hüdroklorotiasiidi (hydrochlorothiazidum).
English: EU/1/09/575/024 280 film-coated tablets (multipack, 20 cartons of 14 tablets) EU/1/09/575/023 280 film-coated tablets (multipack, 4 cartons of 70 tablets) (unit dose)
Estonian: EU/1/09/569/024 280 õhukese polümeerikattega tabletti (hulgipakend, 20 karpi, igaühes 14 tabletti) EU/1/09/569/023 280 õhukese polümeerikattega tabletti (hulgipakend, 4 karpi, igaühes 70 tabletti) (üheannuseline)
English: Each film-coated tablet contains 10 mg amlodipine (as amlodipine besylate), 160 mg valsartan, and 25 mg hydrochlorothiazide.
Estonian: Iga õhukese polümeerikattega tablett sisaldab 10 mg amlodipiini (amlodipinum) (amlodipiinbesülaadina), 160 mg valsartaani (valsartanum) ja 25 mg hüdroklorotiasiidi (hydrochlorothiazidum).
English: EU/1/09/575/012 280 film-coated tablets (multipack, 20 cartons of 14 tablets) EU/1/09/575/011 280 film-coated tablets (multipack, 4 cartons of 70 tablets) (unit dose)
Estonian: EU/1/09/569/012 280 õhukese polümeerikattega tabletti (hulgipakend, 20 karpi, igaühes 14 tabletti) EU/1/09/569/011 280 õhukese polümeerikattega tabletti (hulgipakend, 4 karpi, igaühes 70 tabletti) (üheannuseline)
English: Serum levels of calcium should be periodically monitored during treatment with thiazides.
Estonian: Kui ravi ajal tekib hüperkaltseemia, tuleb ravi Copalia HCT'ga katkestada.Ravi ajal tiasiiddiureetikumidega tuleb seerumi kaltsiumitaset perioodiliselt jälgida.
English: It is available as capsules (150 mg).
Estonian: Erivedget turustatakse kapslitena (150 mg).
English: The recommended dose is one capsule once a day.
Estonian: Soovituslik annus on üks kapsel üks kord ööpäevas.
English: What measures are being taken to ensure the safe and effective use of Erivedge?
Estonian: Mis meetmed võetakse, et tagada Erivedge ohutu ja efektiivne kasutamine?
English: The full EPAR for Erivedge can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Erivedge kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Erivedge vismodegib
Estonian: Erivedge vismodegiib
English: What is Erivedge and what is it used for?
Estonian: Mis on Erivedge ja milleks seda kasutatakse?
English: Erivedge was not compared with another treatment.
Estonian: Erivedget ei võrreldud teiste ravimitega.
English: The patients were given Erivedge until their disease got worse or they could no longer tolerate treatment or withdrew from the study.
Estonian: Patsiente raviti Erivedgega, kuni nende haigus süvenes või nad ei talunud enam ravi või loobusid uuringus osalemast.
English: Other information about Erivedge
Estonian: Muu teave Erivedge kohta
English: The European Commission granted a marketing authorisation valid throughout the European Union for Erivedge on 12 July 2013.
Estonian: Euroopa Komisjon andis Erivedge müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 12. juulil
English: Why is Erivedge approved?
Estonian: Miks Erivedge heaks kiideti?
English: The benefits of continuing treatment should be regularly assessed and the best duration of treatment will vary based on the benefit and side effects experienced by each patient.
Estonian: Ravi jätkamise kasulikkust tuleb korrapäraselt hinnata ja ravi parim kestus oleneb igal patsiendil täheldatavast kasulikkusest ja kõrvalnähtudest.
English: Erivedge was studied in one main study involving 104 patients with either metastatic or locally advanced basal cell carcinoma.
Estonian: Erivedget uuriti ühes põhiuuringus, milles osales 104 patsienti, kellel oli kas metastaatiline või lokaalselt kaugelearenenud basaalrakuline kartsinoom.